Efficacy of lateral bone augmentation performed simultaneously with dental implant placement. A systematic review and meta-analysis by Thoma, Daniel S et al.








Efficacy of lateral bone augmentation performed simultaneously with dental
implant placement. A systematic review and meta-analysis
Thoma, Daniel S ; Bienz, Stefan P ; Figuero, Elena ; Jung, Ronald E ; Sanz-Martin, Ignacio
Abstract: OBJECTIVES To analyze the evidence regarding the efficacy of lateral bone augmentation
procedures in terms of defect resolution in cases of horizontal ridge deficiencies after implant placement.
MATERIALS AND METHODS Included studies met the following inclusion criteria: randomized con-
trolled trials (RCTs) or controlled clinical trials (CCT’s), re-entry procedure to assess defect resolution,
minimum of 10 patients (5 per group). Meta-analyses were performed whenever possible, including sub-
group analysis based on membranes and grafting materials. RESULTS Twenty-eight publications (20
short-term, 8 follow-up studies) were included. The most often used type of intervention was a xeno-
geneic particulated grafting material (XE) and a resorbable collagen membrane (CM). The mean defect
height at baseline amounted to 5.1 mm (range 2.4 - 7.8) and decreased to a mean of 0.9 mm (range
0.2 - 2.2) at re-entry, and the mean defect resolution was 81.3% (range 56.4% - 97.1%). Defect height
reduction was not significantly different using CM +XE as control treatment compared to the combined
data of the respective test groups [n=11; weighted mean difference (WMD) = -0.006mm; 95% CI, -0.61,
0.60; p=0.985]. The absence of any lateral bone augmentation was less favorable than the conjunction of
a membrane and a bone grafting material (n=1; MD = -1.96mm; 95% CI, -3.48, -0.44; p=0.011). The
lack of a grafting material was less favorable than the conjunction of grafting material and membrane
(n=1; MD = -2.44mm; 95% CI, -4.53, -0.35; p=0.022) and the addition of a membrane compared to a
grafting material alone was more favorable (n=3; WMD = 0.97mm; 95% CI, 0.31, 1.64; p=0.004). CON-
CLUSIONS Lateral bone augmentation is a successful treatment modality. For optimal defect height
reduction, a barrier membrane and a grafting material should be combined. This article is protected by
copyright. All rights reserved.
DOI: https://doi.org/10.1111/jcpe.13050
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Objectives: To analyze the evidence regarding the efficacy of lateral bone augmentation 
procedures in terms of defect resolution in cases of horizontal ridge deficiencies after 
implant placement.  
Materials and Methods: Included studies met the following inclusion criteria: 
randomized controlled trials (RCTs) or controlled clinical trials (CCT’s), re-entry 
procedure to assess defect resolution, minimum of 10 patients (5 per group). Meta-
analyses were performed whenever possible, including subgroup analysis based on 
membranes and grafting materials. 
Results: Twenty-eight publications (20 short-term, 8 follow-up studies) were included. 
The most often used type of intervention was a xenogeneic particulated grafting material 
(XE) and a resorbable collagen membrane (CM). The mean defect height at baseline 
amounted to 5.1 mm (range 2.4 - 7.8) and decreased to a mean of 0.9 mm (range 0.2 - 
2.2) at re-entry, and the mean defect resolution was 81.3 % (range 56.4% - 97.1%). 
Defect height reduction was not significantly different using CM +XE as control treatment 
compared to the combined data of the respective test groups [n=11; weighted mean 
difference (WMD) = -0.006mm; 95% CI, -0.61, 0.60; p=0.985]. The absence of any 
lateral bone augmentation was less favorable than the conjunction of a membrane and a 
bone grafting material (n=1; MD = -1.96mm; 95% CI, -3.48, -0.44; p=0.011). The lack 
of a grafting material was less favorable than the conjunction of grafting material and 
membrane (n=1; MD = -2.44mm; 95% CI, -4.53, -0.35; p=0.022) and the addition of a 
membrane compared to a grafting material alone was more favorable (n=3; WMD = 
0.97mm; 95% CI, 0.31, 1.64; p=0.004).  
Conclusions: Lateral bone augmentation is a successful treatment modality. For optimal 




Scientific rationale for the study: Lateral bone augmentation performed 
simultaneously with dental implant placement is a well-established treatment modality. 
The efficacy of the procedure and the influence of various biomaterials on short- and 
longer-term outcomes are insufficiently documented in a systematic review. 
Principal findings: The overall mean vertical defect resolution amounted to 81.3 % 
(range 56.4% - 97.1%). Even though the number of studies included in meta-analysis 
was limited, the combination of a grafting material and a membrane was more favorable 
compared to a membrane or a grafting material alone or the absence of treatment. The 
most often used type of intervention was a xenogeneic particulated grafting material 
(XE) and a resorbable collagen membrane (CM).  
Practical implications: Guided bone regeneration is a successful treatment modality to 
obtain defect resolution at implant dehiscence defects. For optimal defect height 
reduction, a barrier membrane and a grafting material should be combined. CM + XE is 




The use of dental implants is a common procedure to restore missing teeth in both, 
removable and fixed prosthodontics. Expected and reported survival rates of dental 
implants and the respective reconstructions exceed 90% after 5 years (Jung, R. E. et al., 
2012, Pjetursson, B. E. et al., 2012). In the early days, dental implants were 
predominantly placed where a sufficient amount of bone was present. This concept 
changed based on the needs of esthetics and resulted in a so-called prosthetically-driven 
implant placement (Grunder, U. et al., 2005). Due to changes of the ridge profile 
following tooth extraction, the amount of available bone may decrease significantly and 
additional bone regenerative procedures may be required. For such procedures, various 
biomaterials are applied, including autogenous, allogenic, xenogeneic and synthetic bone 
substitute materials as well as resorbable and non-resorbable membranes. From a 
clinical point of view, two clinical research questions arise: i) which materials render the 
best outcomes as determined by a defect resolution and longer-term clinical outcome 
and, ii) is there a need to perform a bone regenerative procedure to treat exposed 
implant threads in the presence of a dehiscence or a fenestration defect. Current 
evidence supports the use of non-resorbable membranes or resorbable membranes. The 
shortcoming of non-resorbable membranes are higher rates of wound dehiscences 
(Zitzmann, N. U. et al., 1997), while for resorbable membranes, a lack of space-
maintenance is reported (Mir-Mari, J. et al., 2016). On the level of the biomaterials, 
autogenous bone has been frequently used, but it may increase patient morbidity due to 
the harvesting procedures (Nkenke, E. and Neukam, F. W., 2014). In order to overcome 
this disadvantage and to obtain a slower degradation rate, bone substitute materials 
have been extensively evaluated (Al-Nawas, B. and Schiegnitz, E., 2014). Still, it is 
difficult for a clinician to choose from the wide variety of biomaterials and membranes 
available in the market, and to understand their predictability in terms of defect 
resolution and longer-term outcomes. 
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Very recently, controlled clinical studies documented that, in the long-run, implant 
surfaces might not be fully covered with bone, but still present pleasing soft tissue 
esthetic and stable levels of the margo mucosae (Benic, G. I. et al., 2012). In addition, 
studies even suggested that an (un)intended exposition of implant threads to the peri-
implant mucosa does only minimally affect peri-implant health and marginal bone levels 
(Jung, R. E. et al., 2017, Schwarz, F. et al., 2012). 
Therefore, the aim of the present systematic review was to analyze the evidence 
regarding the efficacy of lateral bone augmentation procedures in terms of defect 
resolution in cases of horizontal ridge deficiencies after implant placement. 
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MATERIAL AND METHODS 
Development of the protocol 
The study protocol was designed according to the PRISMA (Preferred Reporting Items for 
Systematic Review and Meta-Analysis) statement. Before the start of the systematic 
review, a protocol was developed and registered (Prospero ID: 93196) aiming to answer 
the P.I.C.O. question (Needleman, I. G., 2002) that rendered the following P.I.C.O. 
definitions: 
 
• Population: Patients, older than 18 years and in good general health, requiring the 
placement of one or more dental implants in sites presenting horizontal ridge 
deficiencies.  
• Interventions: Any procedure designed to locally augment the bone laterally 
around an implant to cover exposed threads in dehiscence or fenestration type 
defects (simultaneous approach). The following procedures were considered:  
Guided bone regeneration (GBR) using resorbable or non-resorbable membranes 
alone or with the addition of bone graft substitutes (autografts, xenografts, 
alloplasts or allografts) or bone graft substitutes alone, or ridge 
splitting/expansion techniques.  
• Comparison: any procedure aimed at lateral bone augmentation (simultaneous) or 
the absence of treatment. 
• Outcomes: The mean defect height resolution measured with a caliper or a probe 
at re-entry (in mm and/or %) was considered the primary outcome (Figure 1). A 
defect resolution of 100 % or 0 mm remaining defect height is considered as a 
regeneration up to the implant shoulder. Secondary outcomes were implant 
survival rates (%), marginal bone levels (MBL), occurrence of biological 
complications, necessity of re-grafting at re-entry, defect width resolution (Figure 
1), probing depth (PD), bleeding on probing (BOP), contour changes of the buccal 
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peri-implant tissues and changes of position of the mucosal margin. In addition, 
patient-reported outcomes measures (PROMs) were assessed.  
• Study design: Randomized controlled clinical trials (RCTs), controlled clinical trials 
(CCTs) with a minimum sample size of 10 patients (5 per group) and a re-entry 
procedure. 
Exclusion criteria 
• Studies assessing interventions aimed at staged horizontal and/or vertical bone 
augmentation (GBR, bone blocks, distraction osteogenesis, orthognatic surgery, 
inter-positional grafts, maxillary sinus augmentation, etc.). 
• Studies assessing lateral bone augmentation in conjunction with immediate 
implant placement. 
• Preclinical studies in animal models. 
• Articles published in a different language than Spanish, English or German. 
 
Search strategy 
Three electronic databases were used as sources in the search for studies satisfying the 
inclusion criteria: (1) The National Library of Medicine (MEDLINE via Pubmed); (2) 
Embase; and (3) Cochrane Central Register of Controlled Trials. These databases were 
searched for studies published until March 2018. The search was limited to human 
subjects. A search for gray literature was not attempted. Two independent investigators 
(ISM/SB) performed the study selection, any doubts or disagreements were discussed 
with a third investigator (DTH). Prior to the beginning of the data extraction, a calibrating 
session was performed. Two investigators (ISM/SB) screened 100 titles and abstracts 
and discussed their potential inclusion/exclusion. Data extraction was performed by two 
investigators (ISM, SB) in duplicate and thereafter discussed to find an agreement. 
All reference lists of the selected studies were checked for cross-references. In addition, 
the following journals were hand-searched from year 2005 to 2018: Journal of Clinical 
Periodontology, Journal of Periodontology, Clinical Oral Implants Research, International 
 8 
Journal of Oral & Maxillofacial Implants, European Journal of Oral Implantology, Implant 
Dentistry, International Journal of Oral and Maxillofacial Surgery, Journal of Dental 
Implantology, Journal of Oral and Maxillofacial Surgery, Clinical Implant Dentistry and 
Related Research and Journal of Dental Research. 
Inclusion of articles reporting on the same population 
Articles reporting on the follow-up of a patient population included for analysis of the 
primary outcome were also included in the final selection. In case of several follow-up 
reports, only the longest available follow-up was included, unless there were different 
outcomes of interest reported in the earlier publications. 
Quality assessment 
The quality of the included studies was assessed independently by one of the reviewers 
(ISM). The study designs were evaluated according to the Cochrane Collaboration 
recommendations (Higgins, J. P. et al., 2009). Following these criteria, studies were 
defined as of low, unclear or high risk of bias. 
Data analyses 
The statistical heterogeneity among studies was assessed using the Q test based on chi-
square statistics (Cochran, W. G., 1954) as well as the I2 index (Higgins, J. P. et al., 
2003) in order to know the percentage of variation in the global estimate that was 
attributable to heterogeneity (I2=25%: low; I2=50%: moderate; I2=75%: high 
heterogeneity). 
To summarize and compare studies, mean values of primary (defect height resolution) 
and secondary quantitative outcomes (defect width resolution, MBL, PD, BOP, CBCT 
levels, recession) were directly pooled and analyzed with weighted mean differences 
(WMDs) and 95% confidence intervals (CIs). In the case of dichotomous outcome 
(exposure events), the estimates of the effect were expressed in risk ratios and 95% 
CIs.  Study-specific estimates was pooled with both the fixed and random- effect models 
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(DerSimonian, R. and Laird, N., 1986), and the random-effect model results was 
presented. Three groups of meta-analyses were performed, based on the type of control 
group, either native resorbable collagen membranes combined with a particulate 
xenograft (CM+XE), non-resorbable expanded polytetrafluorethylene membranes with 
any bone substitute (ePTFE+BS) or allograft alone (ALO). In the case of studies with 
more than two arms, each intervention was compared against the control group. In 
addition, a subgroup analysis was performed in each meta-analysis on the selected 
outcome variables using the type of test materials as explanatory variable. 
The publication bias was evaluated using the Begg′s and Egger′s tests for small-study 
effects for the main outcome variable. A sensitivity analysis of the meta-analysis results 
was also performed. Forest plots were created to illustrate the effects of the meta-
analysis and the global estimations. STATA-14® (StataCorp LP, Lakeway Drive, College 
Station, Texas, USA) intercooled software was used to perform all analyses. Statistical 




1. Study characteristics 
 
The electronic search provided a total of 1,245 titles/abstracts (for details refer to Figure 
2). Out of these, 1,179 were excluded (inter-reader agreement = 95.25 %; kappa = 
0.54; p<0.001; 95% CI: 0.44; 0.63). The resulting number of obtained full text articles 
was 66. The hand search provided a further number of 20 publications, resulting in an 
overall number of 86 full text articles. Out of these, 58 were excluded (inter-reader 
agreement = 93.02%; kappa = 0.85, p<0.001; 95% CI: 0.77; 0.98). Finally, 28 
publications met the inclusion criteria and were included (Table 1).  
 
1.1. Exclusion of studies 
 
If clinical trials were potentially eligible for inclusion, but did not provide data on the 
primary outcome, authors were contacted to provide, if available, additional data. 
Reasons for excluding studies were: no surgical re-entry/CBCT data reporting defect 
resolution (n=20), articles in other language (n=1), case series (n=32), other (e.g. 
insufficient data, inappropriate control group, longer follow-up available) (n=5) (see 
reference list “excluded studies”). 
 
1.2. Quality assessment of the included studies 
 
In table 2, the results of the quality assessment are summarized. Sixteen studies of the 
included studies were designed as randomized controlled clinical trials (RCTs). Four 
studies had a controlled clinical trial (CCT) design. In addition, follow-up data were 
provided in 7 RCTs and one CCT. The full checklist (Cochrane Collaboration’s tool for 
assessing the risk of bias) was applied for RCTs and CCTs. Six studies were considered as 
low and ten as unclear risk of bias. The remaining studies were considered to have a high 
risk of bias. 
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1.3. Included studies 
 
The 28 publications meeting the inclusion criteria described RCTs (n=16), CCTs (n=4) or 
follow-up studies with an RCT design (n=7) or a CCT design (n=1). Publication dates 
ranged between 1995 and 2017 for the 26 single-center and the two multicenter studies. 
The studies were performed in University settings (n=25), in private practice (n=2) or 
combined at the University and private practice (n=1).  
 
2. RCTs and CCTs short-term data 
Three out of 20 studies had a split-mouth design (all RCTs) and 17 studies a parallel 
group design. In these studies, two or three types of interventions were reported, 
whereas in one study, late and delayed implant placement treatments were compared. 
Overall, 820 patients with a mean age of 52 years had been treated with 1,069 dental 
implants. Females were 62.3 % and smokers 9.0 %. The smoking status, periodontal and 
systemic health were, however, poorly reported. The drop-out rate ranged between 0 % 
and 20.6 %, resulting in a total number of 800 patients providing data for the primary 
outcome. The observation period ranged between 4 and 18 months. Twenty-six implants 
were lost, resulting in a cumulative implant survival rate of 97.6 %. Implant survival 
rates were not affected by the type of treatment (membrane, grafting material, absence 
of treatment) up to a short-term follow-up of 18 months. 
2.1. Interventions, grafting materials and membranes 
The types of interventions at implants with dehiscence defects are displayed in table 1.  
The primary outcome (defect height reduction) was assessed by surgical re-entry 
procedures after a mean follow-up period of 6.3 months (follow-up range 4-12 months). 
The baseline and re-entry data on defect height as well as the change are summarized in 
table 3. The mean defect height at baseline amounted to 5.1 mm (range 2.4 - 7.8) and 
decreased to a mean of 0.9 mm (range 0.2 - 2.2) at re-entry. This resulted in a mean 
defect resolution of 81.3 % (range 56.4 - 97.1). 
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2.2. Primary outcome 
2.2.1. Effect of type of membrane 
The most often used type of intervention was the combination of a xenogeneic 
particulated grafting material with or without autogenous bone particles and a resorbable 
collagen membrane (n=13). Meta-analyses using a native collagen membrane (CM) in 
conjunction with a xenogeneic particulated grafting material (XE) as control treatment 
demonstrated a significant heterogeneity between the studies (I2=67.1%; p=0.001) 
(Figure 3a). Defect height reduction was not significantly different (weighted mean 
difference (WMD) = -0.006mm; 95% CI, -0.61, 0.60; p=0.985) compared to the 
combined data of the respective test groups (n=11) (Figure 3a). The WMD compared to 
non-resorbable expanded polytetrafluorethylene (ePTFE) plus bone substitute materials 
(BS) (n=2) (-0.43mm; 95% CI, -0.78, -0.08) was significant (p=0.015) in favor of CM. 
The use of a synthetic PEG membrane resulted in a significantly more favorable defect 
height reduction (MD = 1.38mm; 95% CI, 0.39, 2.37; p=0.006) (n=1). All other 
comparisons did not result in significant inter-group differences (Figure 3a).  
The second most commonly used materials were xenogeneic particulated grafting 
materials with or without autogenous bone particles and a membrane (n=6) (Figure 3b). 
Non-resorbable ePTFE membranes plus BS resulted in significantly more favorable 
outcomes (WMD = -1.18mm; 95% CI, -2.28, -0.08; p=0.035) compared to the 
combined data of the respective test groups (n=5); heterogeneity was large though 
(I2=88.4%; p<0.001). Based on three comparative studies using synthetic membranes 
(polylactide/polyglycolide) and BS, ePTFE membranes were significantly more effective 
(WMD = -1.49mm; 95% CI, -1.93, -1.05; p<0.001) (Figure 3b). 
No publication bias for re-entry height changes was detected by Begg (p= 0.755) or 
Egger tests (p=0.547). The sensitivity analyses for this outcome showed that the 
exclusion of a single study did not substantially alter any estimate. 
 13 
 
2.2.2. Effect of placing a membrane 
The effect of placing a membrane in addition to a grafting material (autogenous bone 
chips or allografts) was evaluated in three studies (Fu, J. H. et al., 2014, Park, S. H. et 
al., 2008, Schlegel, A. K. et al., 1998). GBR performed with a membrane was 
significantly more favorable (n=2; WMD = 0.97mm; 95% CI, 0.31, 1.64; p=0.004) 
(Figure 3c) compared to the use of a bone substitute alone. 
2.2.3. Effect of type of grafting material 
The effect of a specific grafting material could not be analyzed due to a large 
heterogeneity of membranes used in the studies. 
2.2.4. Effect of placing a grafting material 
In one study, implant sites were allocated to two treatment modalities (ePTFE membrane 
with or without demineralized freeze-dried bone allograft) (DFDBA) (Mattout, P. et al., 
1995). Defect height reduction was significantly more favorable in case a BS was placed 
(n=1; MD = -2.44mm; 95% CI, -4.53, -0.35; p=0.022). The mean success rates 
(defined as 0% remaining defect height) were 68% (membrane alone) and 90% 
(membrane plus grafting material). 
2.2.5. Absence of treatment 
In the absence of bone regeneration at small bony dehiscence defects (Jung, R. E. et al., 
2017), further buccal bone loss occurred in 42% of the cases compared to 20% of cases 
with GBR. Meta-analyses demonstrated a significantly more favorable defect height 
reduction for sites with GBR compared to no treatment (n=1; MD = -1.96 mm; 95% CI, 
-3.48, -0.44) (p=0.011). The change of the mucosal level (increasing recession) at 
implant sites undergoing GBR amounted to 0.5mm compared to sites left with exposed 
implant threads (0.7mm) (MD = 0.15 mm; 95% CI, -1.99, 2.29; p=0.891). Implant 
survival rates and peri-implant health were, however, not affected by the absence of 
treatment up to 18 months (Jung, R. E. et al., 2017).  
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2.3. Secondary outcomes 
2.3.1. Necessity for re-grafting 
In 5 studies, the necessity for re-grafting (upon re-entry) was described. In three 
studies, no implant site needed an additional bone regenerative procedure (Becker, J. et 
al., 2009, Naenni, N. et al., 2017, Park, S. H. et al., 2008). In two studies, patients in 
need of re-grafting were excluded from the analysis (Lee, D. W. et al., 2015, Lee, J. H. et 
al., 2015). 
2.3.2. Re-entry width 
Based on meta-analyses using CM or ePTFE as control membranes, the only significantly 
different WMD was calculated between CM + XE and ePTFE + BS (n=3) (WMD = 0.52 
mm; 95% CI: 0.27, 0.78; p<0.001) in favor of the non-resorbable membrane. 
2.3.3. Membrane exposure 
Twenty studies explicitly reported membrane exposure between implant placement and 
re-entry (follow-up range 3-12 months). The overall rate of membrane exposure was 
22.7% based on 911 sites. Table 4 displays the rate of exposure depending on the type 
of membrane. Meta-analyses were performed for 11 studies using CM + XE, 5 studies 
using ePTFE plus BS and three studies using allograft (ALO) or autograft as control 
treatment. None of the comparisons was significantly different (p>0.05). However, some 
membranes (cross-linked (x-link) CM, ePTFE, native CM + rhBMP-2, synthetic 
membranes) had a greater risk of exposure than native CM + XE. Moreover, there was a 
tendency of synthetic membranes to increase the risk of exposure compared to ePTFE 
membranes. Exposure of membranes did have a significant effect on defect height 
reduction (n=2) in favor of ePTFE + BS compared to sites with a synthetic resorbable 
membrane + BS (WMD = -1.19 mm; 95% CI: -2.31, -0.08; p=0.036). 
2.3.4. Radiographic outcomes 
CBCT data were reported in two studies (Lee, D. W. et al., 2015, Naenni, N. et al., 
2017). The change in horizontal thickness at the implant shoulder was significantly more 
favorable for non-resorbable ePTFE membranes (0.2±0.4mm) than for resorbable 
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collagen membranes (0.8±0.8mm) during 6 months of healing (Naenni, N. et al., 2017). 
At 1mm below the implant shoulder, the meta-analysis revealed less favorable results for 
CM + XE versus ePTFE + XE (WMD = 0.78 mm; 95% CI, 0.36, 1.20; p<0.001) and 
versus X-link CM + XE (WMD = 0.40 mm; 95% CI, -0.34, 1.14; p=0.292). At 3mm 
below the implant shoulder, results were less favorable for CM + XE versus ePTFE + XE 
(WMD = 0.63 mm; 95% CI, 0.28, 0.98; p<0.001) and versus X-link CM + XE (WMD = 
0.70 mm; 95% CI, -0.01, 1.41; p=0.052) (Lee, D. W. et al., 2015, Naenni, N. et al., 
2017). 
2.3.5. Biological complications 
The reported biological complications up to 18 months included: implant exposure, 
barrier exposure, soft tissue dehiscence, peri-implantitis, recurrent bone loss and bone 
loss >1.5mm. The mean complication rate was 20.8% based on 144 implant sites. This 
data does not include the above-mentioned, specifically reported rate of membrane 
exposure. 
2.3.6. Patient-reported outcomes measures (PROMs)  
None of the studies assessed these outcomes.  
 
 
3. RCTs and CCTs follow-up 
Out of 8 follow-up studies, 7 had a RCT design and one study a CCT design. All of the 
studies with RCT design reported on two different types of interventions and 3 were split-
mouth studies. Overall, the studies provided data on 142 patients and a total number of 
298 dental implants. The drop-out rate ranged between 9.1 % and 64.8 %. Females 
accounted for 68.4 % of the patients. The observation period ranged between 36 and 
150 months. The survival rate of implants after a mean follow-up of 76.5 months was 
95.0%. Implant survival rates were not affected by the type of treatment (membrane, 
grafting material, sites with exposed implant threads) up to 76.5 months of follow-up. 
3.1. Interventions, grafting materials and membranes 
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The original interventions at implants with dehiscence defects are displayed in Table 1.  
The most often used type of intervention was the combination of a xenogeneic 
particulated grafting material and a resorbable collagen membrane (n=5). The second 
most commonly used materials were xenogeneic particulated grafting materials with or 
without autogenous bone particles and an ePTFE membrane (n=2). 
3.2. Outcome measures 
3.2.1. Marginal bone levels 
Combined mesial and distal marginal bone level changes based on 3 studies (Basler, T. 
et al., 2018, Jung, R. E. et al., 2013, Ramel, C. F. et al., 2012) at a mean follow-up of 74 
months (range 36-150) were -0.19mm (range 0.04 to -0.61). Mesial and distal values 
were reported separately in one study (Jung, R. E. et al., 2009). The changes from 
baseline (insertion of prosthetic reconstructions) to 5 years were -0.07 mm (mesial, 
rhBMP-2 group), -0.11 mm (distal, rhBMP-2 group), -0.03 mm (mesial, control without 
rhBMP-2), to -0.13 mm (distal, control without rhBMP-2).  
 
3.2.2. Biological complications 
The reported biological complications after a mean follow-up of 56.8 months (36-96) 
included: recurrent bone loss, mucositis, peri-implantitis, implant exposure, barrier 
exposure, soft tissue dehiscence, peri-implantitis, recurrent bone loss and bone loss 
>1.5mm. The mean complication rate was 14.8% based on 223 implant sites. The mean 
complication rate for non-resorbable ePTFE membranes amounted to 13.9% based on 43 
sites and the mean complication rate for resorbable collagen membranes was 13.6% 
based on 147 sites. The resorbable x-linked and polyethylene glycol membranes had 
complication rates of 44.4% and 16.6% based on 9 and 18 sites respectively. 
3.2.3. BOP/PD/level of the mucosa 
Final PD values were reported in 4 studies (Basler, T. et al., 2018, Jung, R. E. et al., 
2013, Jung, R. E. et al., 2009, Schwarz, F. et al., 2017) and amounted to 3.4mm (2.4 to 
3.9). PD changes amounted to 0.2mm (36 months (Basler, T. et al., 2018)). Bleeding on 
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probing at the last follow-up (36 and 96 months respectively) ranged between 11.0 and 
48.1% (Basler, T. et al., 2018, Schwarz, F. et al., 2017). The level of the mucosa shifted 
more apically ranging between 0.1 and 0.6mm (Jung, R. E. et al., 2013). 
3.2.4. Contour changes 
Contour changes at the buccal aspect of the implant sites between crown insertion and 
the 3-year follow-up were evaluated by means of superimposition of the surface STL files 
and measurement of the mean distance between the surfaces in the relevant area. The 
changes amounted to -0.3mm without significant differences between non-resorbable 
and resorbable membrane sites (Basler, T. et al., 2018). 
3.2.5. Follow-up of implant sites with and without dehiscence defects at re-entry 
One particular study re-grouped the patients at the day of re-entry into three patient 
groups: i) with complete bone fill (no dehiscence), ii) <1mm dehiscence defect and, iii) 
>1mm dehiscence defect. The patients were re-examined at 4 years. A higher rate of 
peri-implantitis and more recession was observed for sites with a larger dehiscence 






The present systematic review identified 28 eligible prospective clinical trials (20 studies 
with shorter-term data; 8 follow-up studies) applying various treatment modalities, 
grafting materials and membranes for lateral ridge augmentation indications.  
The most commonly used treatment option in all included studies was a native collagen 
membrane (CM) in conjunction with a xenogeneic, particulated grafting material (XE). 
Meta-analyses applying CM + XE as control group revealed no significantly different WMD 
compared to the combined data of the respective test groups (n=11). Significant 
differences, however, were observed in direct comparison to the second most common 
membrane, a non-resorbable ePTFE membrane in favor of CM for the primary outcome, 
vertical defect resolution. These data are based on two included studies (Carpio, L. et al., 
2000, Naenni, N. et al., 2017) and are to some extent surprising since the use of an 
ePTFE membrane was considered to be the gold standard for GBR procedure at implant 
sites with dehiscence defects (Benic, G. I. and Hammerle, C. H., 2014). One has to bear 
in mind, however, that ePTFE membranes were superior compared to all other 
comparative treatment modalities if taken as a control group based on meta-analyses in 
the present systematic review. The comparative therapeutic options encompassed: 
synthetic membranes (n=3), no grafting material (n=1) and a cross-linked CM 
(n=1)(Mattout, P. et al., 1995, Schneider, D. et al., 2014, Lorenzoni, M. et al., 1998, 
Moses, O. et al., 2005). Moreover, the effect of GBR is not only assessed by the defect 
resolution, but also by the obtained changes in defect width, height as well as the 
horizontal thickness on the buccal side of the implant. In case, the changes in thickness 
(buccal side of the implant in a horizontal direction) between post-augmentation and 6 
months (at re-entry) are considered, ePTFE membranes are reported to result in 
significantly more favorable outcomes than CM + XE (Naenni, N. et al., 2017). Still, from 
a clinical point of view, defect resolution (vertical bone fill) and not the obtained 
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horizontal thickness at the level of the implant shoulder appear to be more important, 
bearing in mind that the main goal of GBR procedures is to have exposed implant threads 
covered by bone. Based on the meta-analyses, it is difficult to recommend a specific 
treatment modality, since the heterogeneity between the studies was large, applying a 
plethora of barrier membranes and grafting materials. Moreover, WMDs between the 
treatment modalities were for the majority of the comparisons <1mm. The clinical impact 
of such a difference remains questionable.  
Guided bone regeneration relies on the principle of applying a membrane that serves as a 
barrier to prevent soft tissue ingrowth into the defect area (Dahlin, C. et al., 1989). In 
case of applying a non-form-stable resorbable membrane, the placement of a grafting 
material has been recommended to prevent a collapse of the augmented site (Strietzel, 
F. P. et al., 2006, Won, J. Y. et al., 2016). Controversy exists on the need of placing a 
membrane and on the need of a biomaterial to successfully augment bone at buccal 
dehiscence defects. The present systematic review clearly revealed more favorable 
outcomes comparing augmentation procedures with and without membranes. The 
addition of a barrier membrane resulted in a larger defect height reduction of 0.85 up to 
1.51 mm (Fu, J. H. et al., 2014, Park, S. H. et al., 2008, Schlegel, A. K. et al., 1998). 
These outcomes to some extent contradict preclinical and clinical data suggesting the 
periosteum alone can serve as a barrier membrane and may be sufficient for bone 
regenerative procedures for various indications (Yu, Z. et al., 2015). 
Originally, barrier membranes were placed without grafting material, thereby maintaining 
the volume for the blood clot to transform into bone (Schmid, J. et al., 1997), (Buser, D. 
et al., 1998). Meta-analysis demonstrated significantly more favorable outcomes if a 
grafting material was placed. The data are based on a clinical study using DFDBA as 
grafting material in direct comparison to the treatment with membranes (ePTFE) alone 
(Mattout, P. et al., 1995). The calculated WMD was -2.4 mm.  
Biological complications were reported to various extents in the included studies and 
encompassed implant exposure, barrier exposure, soft tissue dehiscence and marginal 
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bone loss, in the short-term. Membrane exposure has often been attributed to the use of 
more form-stable (e.g. cross-linked membrane) or non-resorbable membranes. Even 
though, the incidence of such complications appears to be high for such membranes, all 
types of membranes and combinations with grafting materials were affected with the 
majority of the studies reporting complications rates between 17.5 % and 42.1 %. The 
clinical impact of such complications might depend on the time-point they occur. 
Resorbable collagen membranes tend to expose at an early stage (suture removal), 
synthetic membranes slightly later and non-resorbable membranes appear to be affected 
even during the later healing phase. Early exposure could in part be related to general 
wound healing complications associated with flap design and management, swelling 
following the surgical intervention as well as patient compliance. Delayed membrane 
exposure might be predominantly attributed to a lack of soft tissue integration due to a 
relatively smooth surface or to degradation products of synthetic membranes. In 
contrast, the exposure of cross-linked collagen resorbable membranes has been 
attributed to the chemical and/or physical properties of the respective barriers that affect 
its behavior in case of exposure. The clinical impact (e.g. defect height resolution) of 
such complications has been described in five included studies (Becker, J. et al., 2009, 
Lorenzoni, M. et al., 1998, Park, S. H. et al., 2008, Nemcovsky, C. E. and Artzi, Z., 2002, 
Fu, J. H. et al., 2014). Most of the outcomes demonstrated a defect height reduction 
between 40 % and 60%. No membrane, however, appears to be more favorable and to 
decrease the number of biological complications at least when looking at the raw data 
and the incidences. It has been documented in two cross-sectional studies that implant 
dehiscence defects can be observed on CBCT images at 7 and 10 years post placement of 
dental implants, thereby indicating a failure of the bone augmentation procedure (Benic, 
G. I. et al., 2012, Kuchler, U. et al., 2016). Interestingly, these complications did not 
affect the clinical outcomes at the soft tissue level to the same extent as on the level of 
the bone, with levels of the marginal mucosae being minimally affected. In a RCT (Jung, 
R. E. et al., 2017), the need for GBR procedures at small buccal bone dehiscence defects 
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was evaluated comparing sites with and without GBR. Data up to 18 months, 
demonstrated that in the absence of bone regeneration, further buccal bone loss 
occurred in 42% of the cases compared to 20% of cases with GBR and a significantly 
more favorable defect height reduction for sites with GBR compared to no treatment. On 
the level of the soft tissues, however, the mucosal level was more favorable for sites 
without GBR compared to sites undergoing GBR. Implant survival rates and peri-implant 
health were, however, not affected by the absence of treatment (Jung, R. E. et al., 
2017). One might speculate that on the longer-term, exposed implant threads, covered 
by the peri-implant soft tissues, increase the risk of developing peri-implant diseases. In 
a 4-year follow-up study of a RCT (Schwarz, F. et al., 2012), implant sites with 
successful and failed GBR procedures were compared. More mucosal recession, a higher 
BOP value and therefore a higher risk of developing a peri-implant disease was reported 
for sites with a minimal (1mm) or advanced (>1mm) residual defect height at re-entry. 
The latter two prospective clinical studies indicate the need to regenerate buccal peri-
implant dehiscence defects to maintain peri-implant health over time. 
To some extent disappointing, data on longer-term outcomes following GBR procedures 
were limited. The data are even more limited since all 8 studies were published by two 
University groups only (University of Düsseldorf, University of Zurich). Based on available 
data, radiographic marginal bone level changes appear to be minimal and well in line 
with data on implants being placed in native bone (Benic, G. I. et al., 2017). Clinical 
outcome measures such as PD, PI and the stability of the mucosal margin were stable. 
Moreover, the data (derived from two studies; (Naenni, N. et al., 2017, Lee, J. H. et al., 
2015)) on contour changes at the buccal aspect of implant sites having been treated with 
GBR demonstrated minimal changes over time. On the longer-term, biological 
complications encompassed recurrent bone loss, peri-implant mucositis and peri-
implantitis. The overall complication rate was roughly 15% after a mean follow-up of 5 
years. Differences between the membranes were hardly observed, except for an 
 22 
experimentally x-linked collagen membrane that was reported to have a complication 
rate of 44% (Schwarz, F. et al., 2017, Becker, J. et al., 2009). 
The outcomes of the present systematic review are to some extent limited by the large 
heterogeneity in terms of applied membranes, grafting materials and the respective 
combinations. Furthermore, it was rarely reported whether implants were placed rather 
surgically or prosthetically driven and implant site locations varied across the studies with 
the majority of the studies not reporting details on this. This might have resulted in 
including studies with variable implant site locations and potentially different types of 
defects. In conjunction with a similarly high variability of outcome measures, the data did 
not allow to draw conclusions being able to identify a superior treatment modality. 
Moreover, longer-term data were only published by two research groups and based on 5 
patient cohorts. Future patient populations following GBR are strongly encouraged to be 
followed for a longer time-span than just the re-entry procedures. In addition, outcome 
measures such as PROMs and reporting of early (wound dehiscences versus membrane 
exposure) and late (peri-implant diseases) biological complications should be reported 






Lateral bone augmentation via GBR at sites presenting peri-implant dehiscence defects 
upon implant placement is a successful treatment modality to obtain defect resolution.  
The review predominantly revealed: 
• a native collagen membrane (CM) in conjunction with a xenogeneic, particulated 
grafting material (XE) was the most commonly used treatment option;  
• meta-analyses applying CM + XE as control group did not result in a significantly 
more favorable defect resolution compared to the combined data of the respective 
test groups (n=11); 
• a significantly more favorable defect resolution for CM + XE compared to the 
second most common membrane, a non-resorbable ePTFE membrane; 
• for optimal defect height resolution, a barrier membrane and a grafting material 
should be combined;  
• a rate of biological complications of 20.8%;  
• relatively small changes of the buccal contour over 3 years post insertion of final 
reconstructions and a survival rate of implants after a mean follow-up of 76.5 
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Figure 1. The reduction of the defect height at re-entry compared with the measurement 
prior to augmentation was the primary outcome. Resolution of the defect width was a 
secondary outcome. 
 
Figure 2. Flowchart containing the search strategy and respective selection process. 
 
Figure 3a. Forest plot illustrating the results in terms of defect height reduction from 
meta-analysis of all trials with a resorbable collagen membrane in combination with a 
particulate xenograft (CM+XE) as a control. ePTFE = expanded polytetrafluorethylene; 
BS = bone substitute; BMP-2 = recombinant human bone morphogenetic protein 2; beta 
TCP = beta tri-calcium phosphate. 
 
Figure 3b. Forest plot illustrating the results in terms of defect height reduction from the 
meta-analysis of all trials with a non-resorbable expanded polytetrafluorethylene 
membrane in combination with any bone substitute (ePTFE+BS) as a control. CM = 
collagen membrane. 
 
Figure 3c. Forest plot illustrating the results in terms of defect height reduction from the 
meta-analysis of all trials with allograft and no membrane (ALO) as a control. CM = 
collagen membrane. 
 
Table 1. Methodological characteristics of the selected studies, the types of interventions 
and the outcomes measured. RCT = Randomized clinical trial; CCT = Controlled clinical 
trial; Follow-up = months(mean); NR = Not reported; ePTFE = expanded 
polytetrafluorethylene; rhBMP-2 = recombinant human bone morphogenetic protein 2; 
DFDBA = Demineralized freeze dried bone allograft; beta TCP = beta tri-calcium 
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phosphate; HA = Hydroxyapatite; IS = Implant survival; SR = success rate (procedure); 
RN = Regrafting necessity; WR = Width reduction; HR = Height reduction; EX = 
Membrane exposure / wound dehiscence; EXW = Exposed site width reduction; EXH = 
Exposed site height reduction; NEXW = Non-exposed site width reduction; NEXH = Non-
exposed site height reduction; MBL = Marginal bone levels assessed radiographically 
(mesial and distal combined); HT0 = horizontal thickness at implant shoulder (CBCT 
assessment); HT1 = horizontal thickness at 1 mm below the implant shoulder (CBCT 
assessment); HT3 = horizontal thickness at 3 mm below implant shoulder (CBCT 
assessment); BC = biological complications (i.e. mucositis, peri-implantitis, bone loss); 
PPD = Peri-implant probing depth; BOP = Bleeding on probing; ML = Midfacial mucosal 
level; STV = Soft tissue volume. 
 
Table 2. Results of the quality assessment. Cochrane Collaboration’s tool for assessing 
the risk of bias was applied for all studies. 
 
Table 3. Results of all studies with a re-entry measurement in terms of defect height. 
The means and standard deviations (SD) of baseline and re-entry outcomes are 
displayed as well as the changes. NR = Not reported; ePTFE = expanded 
polytetrafluorethylene; rhBMP-2 = recombinant human bone morphogenetic protein 2; 
DFDBA = Demineralized freeze dried bone allograft; beta TCP = beta tri-calcium 
phosphate; HA = Hydroxyapatite. 
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